Meeting
2021 ASCO Annual Meeting
Compliance with germline testing in pancreatic cancer in a rural tertiary care hospital.
Authors
Catherine Travaline
Geisinger Medical Center, Danville, PA
Catherine Travaline , Leighton Andrew Elliott , Nadia N. Ramdin , Joseph Vadakara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10599)
DOI
10.1200/JCO.2021.39.15_suppl.10599
Abstract #
10599
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
Single-center comparison of cancer genetics referral rates for patients with pancreatic cancer following implementation of a best practice advisory: A quality improvement project.
First Author: Stephanie Rivera Morales
Poster
2020 ASCO Quality Care Symposium
Improving the referral rate of universal genetic counseling for pancreatic ductal adenocarcinoma (PDAC) at the Cleveland Clinic Taussig Cancer Center: A quality improvement project.
First Author: Kanika G. Nair
Poster
2023 ASCO Breakthrough
Deciphering the tumor microenvironment (TME) dynamics in advanced colorectal (CRC) and pancreatic cancers (PDAC) treated with durvalumab (D) with olaparib (O) or cediranib (C): Results from a phase 2 randomized trial.
First Author: Alberto Hernando-Calvo
Poster
2023 ASCO Annual Meeting
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
First Author: Vincent Chung